Developing mRNA vaccines for certain viral infections
Project 2: mRNA vaccine development against Bunyaviruses, Paramyxoviruses and Picornaviruses
This study is working on new mRNA vaccines to help protect people from certain viruses that could cause serious outbreaks, using a special method that makes it easier and faster to produce the vaccines, and they will test how well these vaccines work in animals before they are used in humans.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California-Irvine NIH-funded |
| Lab location | 1 site (Irvine, United States) |
| Project ID | NIH-10863343 on NIH RePORTER |
What this research studies
This research focuses on creating mRNA vaccines to protect against Bunyaviruses, Paramyxoviruses, and Picornaviruses, which have the potential to cause pandemics. The approach utilizes a lipid nanoparticle (LNP) platform that allows for rapid and scalable vaccine production without the need for complex infrastructure. By formulating multiple antigen-encoding mRNAs into a single vaccine, the goal is to generate strong and long-lasting immune responses. The effectiveness of these vaccines will be evaluated in animal models to ensure their protective capabilities.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research would include individuals at risk of exposure to these viruses or those living in areas prone to outbreaks.
Not a fit: Patients who are not at risk for these specific viral infections or who have already been vaccinated against them may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective vaccines that prevent future viral pandemics, ultimately saving lives and reducing healthcare burdens.
How similar studies have performed: Previous research has shown promise in using mRNA technology for vaccine development, particularly in the context of COVID-19, indicating a potential for success in this novel application.
Where this research is happening
Irvine, United States
- University of California-Irvine — Irvine, United States (Active)
Researchers
- Principal investigator: Pardi, Norbert — University of California-Irvine
- Study coordinator: Pardi, Norbert
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.